BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38436956)

  • 21. Association of Fluoroquinolone Use With Short-term Risk of Development of Aortic Aneurysm.
    Newton ER; Akerman AW; Strassle PD; Kibbe MR
    JAMA Surg; 2021 Mar; 156(3):264-272. PubMed ID: 33404647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-Based Assessment of Aortic-Related Outcomes in Aortic Dissection, Intramural Hematoma, and Penetrating Aortic Ulcer.
    Weiss S; Sen I; Huang Y; Harmsen WS; Bower TC; Oderich GS; Goodney PP; DeMartino RR
    Ann Vasc Surg; 2020 Nov; 69():62-73. PubMed ID: 32561245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
    Hackshaw MD; Nagar SP; Parks DC; Miller LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aneurysm and Artery Dissection Following the Use of Vascular Endothelial Growth Factor Inhibitor: A Real-World Analysis Using a Spontaneous Reporting System.
    Wang S; Chen M; Zhang X; Zhang L; Jia M; Shen Z; Wang J; Zhao B; Gong Y; Gong J
    J Am Heart Assoc; 2021 Dec; 10(23):e020844. PubMed ID: 34845918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    Circulation; 2017 Feb; 135(8):815-817. PubMed ID: 28223329
    [No Abstract]   [Full Text] [Related]  

  • 27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Aortic Aneurysm and Dissection in Patients with Tuberculosis: A Nationwide Population-Based Cohort Study.
    Chen MT; Chung CH; Ke HY; Peng CK; Chien WC; Shen CH
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and risk analysis of aortic aneurysm and aortic dissection among patients with systemic lupus erythematosus: a nationwide population-based study in Taiwan.
    Wang SH; Chang YS; Liu CJ; Lai CC; Chen TJ; Chen WS
    Lupus; 2014 Jun; 23(7):665-71. PubMed ID: 24554710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aortic dissection during antiangiogenic therapy with sunitinib. A case report.
    Formiga MN; Fanelli MF
    Sao Paulo Med J; 2015; 133(3):275-7. PubMed ID: 25351639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Anti-Vascular Endothelial Growth Factor Drugs and Ocular Adverse Events.
    Fraunfelder FT; Fraunfelder FW
    J Ocul Pharmacol Ther; 2018; 34(6):432-435. PubMed ID: 30004830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine-Preventable Infections Among Solid Organ Transplant Recipients in Switzerland.
    Walti LN; Mugglin C; Mombelli M; Manuel O; Hirsch HH; Khanna N; Mueller NJ; Berger C; Boggian K; Garzoni C; Neofytos D; van Delden C; Mäusezahl M; Hirzel C;
    JAMA Netw Open; 2023 Apr; 6(4):e2310687. PubMed ID: 37115546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population-based propensity score-matched cohort study.
    Garg M; Venugopalan V; Vouri SM; Diaby V; Iovine NM; Park H
    Pharmacotherapy; 2023 Sep; 43(9):883-893. PubMed ID: 37381584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial Thoracic Endovascular Aortic Repair vs Medical Therapy for Acute Uncomplicated Type B Aortic Dissection.
    Weissler EH; Osazuwa-Peters OL; Greiner MA; Hardy NC; Kougias P; O'Brien SM; Mark DB; Jones WS; Secemsky EA; Vekstein AM; Shalhub S; Mussa FF; Patel MR; Vemulapalli S
    JAMA Cardiol; 2023 Jan; 8(1):44-53. PubMed ID: 36334259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study.
    Pasternak B; Inghammar M; Svanström H
    BMJ; 2018 Mar; 360():k678. PubMed ID: 29519881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis.
    Hsu CY; Su YW; Chen YT; Tsai SH; Chang CC; Li SY; Huang PH; Chen JW; Lin SJ
    Cardiovasc Diabetol; 2016 Sep; 15(1):125. PubMed ID: 27585542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
    Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
    JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
    Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
    Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
    Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.